NCT03361215 Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis
| NCT ID | NCT03361215 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Schleswig-Holstein |
| Condition | Atopic Dermatitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2015-03-16 |
| Primary Completion | 2028-03-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2015-03-16 with a primary completion date of 2028-03-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The clinical study investigates the long-term course of disease in patients with chronic inflammatory skin diseases (atopic eczema and psoriasis) and the impact of tarheted therapies on the clinical and molecular level. For this purpose, patients are asked to take part in regular examinations and data collections, and to donate biomaterials (blood, skin biopsies, skin swabs, tape strips, stool samples). Blood samples are used to analyze inflammation messengers. Punch biopsies from lesional and non-lesional skin areas are used to analyze gene expression. Tape strips are pieces of transparent adhesive tapes to strip off most of the horny layer that will be used to examine mRNA and protein expression. The skin smears are superficial smears of three areas of skin with cotton swabs, which are used to examine bacteria on the skin. Overall, the study will help to monitor the disease course clinically and on the molecular level in participating patients for at least ten years and to collect information about the impact of various external factors including treatments. The study has no effect on the therapies of the disease, it serves only the accompanying data collection
Eligibility Criteria
Inclusion Criteria: * Patients with a clinical diagnosis of atopic dermatitis, psoriasis or autoimmune skin disease * Written informed consent obtained from the subject Exclusion Criteria: * Patients who decline participation In patients\<18 years of age no biopsies will be taken
Contact & Investigator
Stephan Weidinger, Prof. Dr.
PRINCIPAL INVESTIGATOR
Dept. of Dermatology University Hospital Kiel
Frequently Asked Questions
Who can join the NCT03361215 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 100 Years, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03361215 currently recruiting?
Yes, NCT03361215 is actively recruiting participants. Contact the research team at sweidinger@dermatology.uni-kiel.de for enrollment information.
Where is the NCT03361215 trial being conducted?
This trial is being conducted at Kiel, Germany.
Who is sponsoring the NCT03361215 clinical trial?
NCT03361215 is sponsored by University Hospital Schleswig-Holstein. The principal investigator is Stephan Weidinger, Prof. Dr. at Dept. of Dermatology University Hospital Kiel. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.